Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Halda, Accent and Vividion take more projects into phase 1.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Opdualag chalks up another failure, this time in the extension of an approved use.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
